

# Srikala S Sridhar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5742977/publications.pdf>

Version: 2024-02-01

93  
papers

5,680  
citations

257429  
24  
h-index

79691  
73  
g-index

93  
all docs

93  
docs citations

93  
times ranked

6845  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic therapy in bladder preservation. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 39-47.	1.6	8
2	The survival outcomes of the metastatic renal cell carcinoma with rhabdoid differentiation in immunotherapy era: Princess Margaret Cancer Center experience.. Journal of Clinical Oncology, 2022, 40, 333-333.	1.6	0
3	Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.. Journal of Clinical Oncology, 2022, 40, 332-332.	1.6	0
4	The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210948.	3.2	2
5	Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma (mUC) treated with durvalumab (D) with or without tremelimumab (T) in the DANUBE study.. Journal of Clinical Oncology, 2022, 40, 4564-4564.	1.6	1
6	Neoadjuvant Versus Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Microsimulation Model. Clinical Genitourinary Cancer, 2021, 19, e135-e147.	1.9	4
7	Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer. European Urology, 2021, 79, 177-179.	1.9	2
8	Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature. Oncology and Therapy, 2021, 9, 21-39.	2.6	20
9	Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nature Reviews Urology, 2021, 18, 104-114.	3.8	57
10	A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer.. Journal of Clinical Oncology, 2021, 39, TPS501-TPS501.	1.6	2
11	Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer. Current Oncology Reports, 2021, 23, 36.	4.0	2
12	Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 835.e1-835.e7.	1.6	3
13	The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review. Oncologist, 2021, 26, e1381-e1394.	3.7	8
14	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. Cancer Medicine, 2021, 10, 5775-5782.	2.8	7
15	Neurocognitive outcomes following fetal exposure to chemotherapy for gestational breast cancer: A Canadian multi-center cohort study. Breast, 2021, 58, 34-41.	2.2	1
16	Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma. Canadian Urological Association Journal, 2021, 16, .	0.6	2
17	Metastatic Urothelial Cancer: a rapidly changing treatment landscape. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110473.	3.2	19
18	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. Canadian Urological Association Journal, 2021, 16, .	0.6	3

#	ARTICLE	IF	CITATIONS
19	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. PLoS ONE, 2021, 16, e0259272.	2.5	4
20	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 3.e17-3.e27.	1.6	29
21	Impact of age at diagnosis of de novo metastatic prostate cancer on survival. Cancer, 2020, 126, 986-993.	4.1	36
22	Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 559-566.	1.3	3
23	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 2020, 383, 1218-1230.	27.0	802
24	A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association. Canadian Urological Association Journal, 2020, 14, 163-168.	0.6	20
25	Transitioning to a New Normal in the Post-COVID Era. Current Oncology Reports, 2020, 22, 73.	4.0	10
26	Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2020, 14, 404-410.	0.6	3
27	Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. Npj Breast Cancer, 2020, 6, 22.	5.2	7
28	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. Canadian Urological Association Journal, 2020, 14, E373-E382.	0.6	8
29	Key Perspectives on Managing Older Patients with Prostate Cancer: What We Know About the Fit and What We Need to Know About the Frail. European Urology Oncology, 2020, 3, 410-411.	5.4	0
30	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. Bladder Cancer, 2020, 6, 363-392.	0.4	1
31	EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology, 2020, 38, 1041-1049.	1.6	159
32	Is it time to redefine cisplatin ineligibility in metastatic urothelial cancer?. European Journal of Cancer, 2020, 127, 158-159.	2.8	1
33	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions. Current Oncology Reports, 2020, 22, 14.	4.0	16
34	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text). Canadian Urological Association Journal, 2020, 15, E81-9.	0.6	10
35	Enfortumab Vedotin in urothelial cancer. Therapeutic Advances in Urology, 2020, 12, 175628722098019.	2.0	24
36	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma. Canadian Urological Association Journal, 2019, 13, 318-327.	0.6	8

#	ARTICLE	IF	CITATIONS
37	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , 2019, 24, 1188-1194.	3.7	32
38	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naïve and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, 17-23.	0.6	17
39	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 7-14.e3.	1.9	9
40	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 38-45.	1.9	29
41	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. <i>European Urology Focus</i> , 2019, 5, 242-249.	3.1	11
42	Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer. <i>Oncotarget</i> , 2019, 10, 2947-2958.	1.8	27
43	The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer. <i>Journal of Urology</i> , 2018, 200, 283-291.	0.4	22
44	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. <i>European Urology Focus</i> , 2018, 4, 937-945.	3.1	7
45	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e233-e242.	1.9	8
46	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 159-168.	2.5	27
47	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2018, 13, 230-238.	0.6	51
48	Prime time for immunotherapy in advanced urothelial cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 24-32.	1.1	2
49	Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. <i>Canadian Urological Association Journal</i> , 2018, 12, E365-E372.	0.6	7
50	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2018, 12, E281-97.	0.6	9
51	The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study. <i>Bladder Cancer</i> , 2018, 4, 185-194.	0.4	19
52	Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4505-4505.	1.6	6
53	Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 328-334.	1.6	29
54	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , 2017, 389, 67-76.	13.7	1,728

#	ARTICLE	IF	CITATIONS
55	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>European Urology</i> , 2017, 71, 281-289.	1.9	56
56	Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. <i>JAMA Oncology</i> , 2017, 3, e172411.	7.1	750
57	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, 2299-2305.	1.6	241
58	Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. <i>British Journal of Cancer</i> , 2016, 114, 207-212.	6.4	53
59	Complete Responses with Targeted Therapy in Metastatic Renal Cell Carcinoma: Balancing Efficacy and Toxicity. <i>European Urology</i> , 2016, 70, 476-477.	1.9	0
60	It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2016, 70, 263-264.	1.9	4
61	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. <i>Canadian Urological Association Journal</i> , 2016, 10, 25.	0.6	17
62	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , 2016, 10, 46.	0.6	55
63	Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. <i>Journal of Geriatric Oncology</i> , 2015, 6, 23-28.	1.0	24
64	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 53-64.	1.6	11
65	Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e229-e233.	1.9	42
66	Opportunities to improve clinical trial design in urothelial bladder cancer. <i>Clinical Research and Regulatory Affairs</i> , 2015, 32, 61-69.	2.1	0
67	Evaluation of second line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first line cediranib. <i>Canadian Urological Association Journal</i> , 2014, 8, 398.	0.6	6
68	Practice patterns and perceptions of survivorship care in Canadian genitourinary oncology: A multidisciplinary perspective. <i>Canadian Urological Association Journal</i> , 2014, 8, 409.	0.6	2
69	Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment. <i>European Urology</i> , 2014, 65, 289-299.	1.9	113
70	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2014, 32, 1005-1016.	2.6	29
71	Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. <i>European Journal of Cancer</i> , 2014, 50, 2399-2407.	2.8	14
72	The Importance of Surgeon Characteristics on Impacting Oncologic Outcomes for Patients Undergoing Radical Cystectomy. <i>Journal of Urology</i> , 2014, 192, 714-720.	0.4	22

#	ARTICLE	IF	CITATIONS
73	Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).. Journal of Clinical Oncology, 2014, 32, 5062-5062.	1.6	3
74	Low-dose abiraterone (abi) with food in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre experience.. Journal of Clinical Oncology, 2014, 32, 5077-5077.	1.6	1
75	Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.. Journal of Clinical Oncology, 2014, 32, 159-159.	1.6	8
76	Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience.. Journal of Clinical Oncology, 2014, 32, 61-61.	1.6	2
77	Evaluation of the neutrophil-lymphocyte ratio (NLR) during neoadjuvant chemotherapy (NC) for muscle-invasive bladder cancer (MIBC) and correlation with pathologic response to treatment.. Journal of Clinical Oncology, 2014, 32, 351-351.	1.6	0
78	Concurrent cisplatin and radiotherapy: Decision making, tolerability, and outcomes for patients treated in a multidisciplinary bladder clinic.. Journal of Clinical Oncology, 2014, 32, 320-320.	1.6	3
79	Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncology, The, 2013, 14, 769-776.	10.7	124
80	A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Investigational New Drugs, 2013, 31, 1008-1015.	2.6	28
81	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. European Urology, 2013, 63, 717-723.	1.9	104
82	Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC). Journal of Cancer, 2013, 4, 304-314.	2.5	26
83	Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC).. Journal of Clinical Oncology, 2013, 31, 5058-5058.	1.6	2
84	Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2013, 31, 4524-4524.	1.6	0
85	Impact of endocrine therapy in early-stage breast cancer on time to locoregional recurrence.. Journal of Clinical Oncology, 2013, 31, 64-64.	1.6	0
86	Does the addition of molecular targeted therapy to standard treatments lead to better or worse outcomes overall? A systematic review of EGFR-targeted therapies used in combination with standard treatments.. Journal of Clinical Oncology, 2012, 30, 2572-2572.	1.6	1
87	Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2012, 30, 4525-4525.	1.6	2
88	Urothelial cancer: Gender discrepancies and impact on overall survival.. Journal of Clinical Oncology, 2012, 30, e15020-e15020.	1.6	0
89	Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.. Journal of Clinical Oncology, 2012, 30, 4522-4522.	1.6	1
90	A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 927-933.	2.3	22

#	ARTICLE	IF	CITATIONS
91	Raf kinase as a target for anticancer therapeutics. Molecular Cancer Therapeutics, 2005, 4, 677-685.	4.1	235
92	Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer, 2003, 42, 81-91.	2.0	89
93	Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncology, The, 2003, 4, 397-406.	10.7	268